Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, New England Journal of Medicine	2009	3.8K
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, Fernando Rivera, Éva Remenár, New England Journal of Medicine	2008	3.7K
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, New England Journal of Medicine	2008	3.6K
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Rafael G. Amado, Michael Wolf, Marc Peeters, Journal of Clinical Oncology	2008	3.1K
<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre, Cancer Research	2006	2.2K
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt, The Lancet Oncology Advanced HeadNeck CancerRadiation TherapyMedicineRandomised Trial	2009	2K
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Journal of Clinical Oncology	2008	1.6K
Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, Journal of Clinical Oncology Kras MutationsGastrointestinal OncologyMedicineBraf MutationsImmunology	2008	1.6K
<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige, Journal of Clinical Oncology	2008	1.4K

Page 1